Author's response to reviews

Title: Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers

Authors:

Makito Miyake (Makito.miyake@orlandohealth.com)
Adrienne Lawton (Adrienne.lawton@orlandohealth.com)
Steve Goodison (goodison.steve@gmail.com)
Virginia Urquidi (urkidi55@gmail.com)
Evan Gomes Giacoia (Evan.gomesgiacoia@orlandohealth.com)
Ge Zhang (Ge.zhang@orlandohealth.com)
Shanti Ross (Shanti.ross@orlandohealth.com)
Jeongsoon Kim (Jeongsoon.kim@orlandohealth.com)
Charles J. Rosser (deacdoc@aol.com)

Version: 2 Date: 10 June 2013

Author's response to reviews: see over
RE: Manuscript submitted to BMC Cancer

Dear Editor,

It is with great pleasure that I resubmit my manuscript entitled ‘Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers’ to your esteemed journal BMC Cancer. We found the reviewers’ comments quite constructive and have modified the manuscript based on these suggestions. Attached is a list outlining the point by point responses to the editor reviewers as well as the revised manuscripts with changes highlighted.

We are very excited about these findings and hope that BMC Cancer will favorably review the manuscript. If you should have any questions or concerns, please do not hesitate to contact me.

Regards,

Charles Joel Rosser, M.D., M.B.A., F.A.C.S.
Chief of Urologic Oncology
Professor, University of Central Florida, College of Medicine
1400 S. Orange Avenue, MP 700
Orlando, FL 32806
Tel: 321.841.5157
Fax: 407.843.6290
Email: Charles.rosser@orlandohealth.com
Response to editor and reviewers’ comments.

Editor
1) Please specify the name of the Ethics committee that approved the study.
This was clarified.

2) Please re-format Authors Contribution section according to our guidelines.
This was reformatted.

Reviewer #1
1. It would be interesting to test this marker in a series of pT1 tumors and study its association with progression-free survival. To be able to predict progression in this subgroup would solve a major clinical problem.

This is a great point. Our group has developed an international bladder biomarker working group. We will take this very salient question to the group in hopes of exploring ASAP.

2. Minor essential revision: references 28 and 29 refer to the correct first authors, but not to the correct papers. The correct papers are mentioned in figure 4.

These two issues were corrected.

Reviewer #2
1. Only one typo has been found and should be corrected. In Page 8, line 6, “significantly higher in patients with MIBC relative to NMIBC (p= 0.0028), and that that CXCL1”. Two “that” should be altered to one “that”.

This typo was corrected.